The ciliary body of muscles and ligaments secretes aqueous humor, the fluid that feeds the
cornea, iris and lens of the eye, and removes the waste products of metabolism. This fluid
normally drains away just as fast as it is created.

If the filter covering the eye’s drain pipe, doesn’t perform properly, aqueous humor builds up between the iris and the cornea, increasing the intraocular eye pressure. As this intraocular eye pressure continues to build, the optic nerve is damaged. This damage is permanent and irreversible.

The first step of treatment is to lower the elevated intraocular eye pressure and this must be followed by surgery to open up the drainpipe. Measurement of the intraocular eye pressure is
not that straight forward as techniques used usually involve indirect methods.

During surgery, it is possible to implant a wireless MEMS pressure sensor in a protected zone of the eye and perform direct pressure measurements. Such device is currently under development at MEMSCAP under contract manufacturing services.

The goal of the artificial heart is to provide an answer to the worldwide health challenge which is the treatment of advanced heart failure.

The CARMAT patented artificial heart prototype respects the biocompatibility criteria enabling its implantation in the human body. Its features are similar to a biological heart, both on the physiological and the anatomy levels.

The system, composed from an implantable part, a portable part as well as external devices
supplying power and assuring its control and monitoring, integrates MEMSCAP sensors to automatically regulate cardiac output and frequency in function of the patient physiological needs, such as physical effort.